A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

762

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Interventions

BIOLOGICAL: Pegozafermin
DRUG: Placebo

Sponsor

89bio, Inc.